Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.00
-92.0%
$0.01
$0.00
$0.75
$13K-2.412,375 shs36,000 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.47
-9.3%
$0.37
$0.80
$1.82
$4.26M2.034,760 shs177,725 shs
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
$0.00
$0.00
$0.15
$4.96M1.5312,042 shsN/A
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
$0.13
$0.12
$0.05
$0.20
$1.02M-0.143,315 shs250 shs
Williston Holding Co. stock logo
WHCA
Williston
$0.00
$0.00
$0.00
N/AN/AN/AN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%-92.00%-90.00%-98.99%-99.27%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
+5.92%+29.75%+9.57%-0.19%+31.19%
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
0.00%0.00%0.00%0.00%-99.93%
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
0.00%-19.12%-3.56%+3.92%+12.26%
Williston Holding Co. stock logo
WHCA
Williston
0.00%0.00%0.00%0.00%-99.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/AN/AN/AN/AN/AN/A
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/AN/AN/AN/A
Williston Holding Co. stock logo
WHCA
Williston
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00
N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00
N/AN/AN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
0.00
N/AN/AN/A
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
0.00
N/AN/AN/A
Williston Holding Co. stock logo
WHCA
Williston
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
$660K0.00N/AN/A($0.32) per share0.00
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
$9.09M0.11N/AN/A($0.49) per share-0.26
Williston Holding Co. stock logo
WHCA
Williston
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/A
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
-$210K-$0.04N/AN/A-3.39%N/A-5.71%8/11/2025 (Estimated)
Williston Holding Co. stock logo
WHCA
Williston
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest IPCIF, ACUR, WHCA, ISCO, and ICOTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/A-$0.03N/A-$0.03N/A$2.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/AN/AN/A
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A
Williston Holding Co. stock logo
WHCA
Williston
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/A
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/A
0.75
0.51
Williston Holding Co. stock logo
WHCA
Williston
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
1066.50 million53.07 millionNot Optionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
1033.09 million32.51 millionNot Optionable
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
308.00 million1.48 millionNot Optionable
Williston Holding Co. stock logo
WHCA
Williston
N/AN/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Top Headlines

View All Headlines
Acura Pharmaceuticals stock logo

Acura Pharmaceuticals OTCMKTS:ACUR

$0.0002 0.00 (-92.00%)
As of 07/1/2025 09:30 AM Eastern

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

iCo Therapeutics stock logo

iCo Therapeutics OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Intellipharmaceutics International stock logo

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

International Stem Cell stock logo

International Stem Cell OTCMKTS:ISCO

$0.13 0.00 (0.00%)
As of 11:13 AM Eastern

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

Williston stock logo

Williston OTCMKTS:WHCA

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.